New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach

Receptor activator of nuclear factor κB (RANK) and its ligand (RANKL) play key roles in bone metabolism and the immune system. The RANK/RANKL complex has also been shown to be critical in the formation of mammary epithelia cells. The female hormones estradiol and progesterone closely control the act...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Magdalena Woźniczka, Katarzyna Błaszczak-Świątkiewicz
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	RANK-RANKL system antiprogestin mesoprogestin osteoporosis hormone-dependent diseases Organic chemistry QD241-441
Acceso en línea:	https://doaj.org/article/7b10aaf7ac6e4049a35883c746c27a12
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7b10aaf7ac6e4049a35883c746c27a12
record_format	dspace
spelling	oai:doaj.org-article:7b10aaf7ac6e4049a35883c746c27a122021-11-11T18:29:27ZNew Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach10.3390/molecules262164911420-3049https://doaj.org/article/7b10aaf7ac6e4049a35883c746c27a122021-10-01T00:00:00Zhttps://www.mdpi.com/1420-3049/26/21/6491https://doaj.org/toc/1420-3049Receptor activator of nuclear factor κB (RANK) and its ligand (RANKL) play key roles in bone metabolism and the immune system. The RANK/RANKL complex has also been shown to be critical in the formation of mammary epithelia cells. The female hormones estradiol and progesterone closely control the action of RANKL with RANK. Blood concentration of these sex hormones in the postmenopausal period leads to an increase in RANK/RANKL signaling and are a major cause of women’s osteoporosis, characterized by altered bone mineralization. Knowledge of the biochemical relationships between hormones and RANK/RANKL signaling provides the opportunity to design novel therapeutic agents to inhibit bone loss, based on the anti-RANKL treatment and inhibition of its interaction with the RANK receptor. The new generation of both anti- and mesoprogestins that inhibit the NF-κB-cyclin D1 axis and blocks the binding of RANKL to RANK can be considered as a potential source of new RANK receptor ligands with anti-RANKL function, which may provide a new perspective into osteoporosis treatment itself as well as limit the osteoporosis rise during breast cancer metastasis to the bone.Magdalena WoźniczkaKatarzyna Błaszczak-ŚwiątkiewiczMDPI AGarticleRANK-RANKL systemantiprogestinmesoprogestinosteoporosishormone-dependent diseasesOrganic chemistryQD241-441ENMolecules, Vol 26, Iss 6491, p 6491 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	RANK-RANKL system antiprogestin mesoprogestin osteoporosis hormone-dependent diseases Organic chemistry QD241-441
spellingShingle	RANK-RANKL system antiprogestin mesoprogestin osteoporosis hormone-dependent diseases Organic chemistry QD241-441 Magdalena Woźniczka Katarzyna Błaszczak-Świątkiewicz New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach
description	Receptor activator of nuclear factor κB (RANK) and its ligand (RANKL) play key roles in bone metabolism and the immune system. The RANK/RANKL complex has also been shown to be critical in the formation of mammary epithelia cells. The female hormones estradiol and progesterone closely control the action of RANKL with RANK. Blood concentration of these sex hormones in the postmenopausal period leads to an increase in RANK/RANKL signaling and are a major cause of women’s osteoporosis, characterized by altered bone mineralization. Knowledge of the biochemical relationships between hormones and RANK/RANKL signaling provides the opportunity to design novel therapeutic agents to inhibit bone loss, based on the anti-RANKL treatment and inhibition of its interaction with the RANK receptor. The new generation of both anti- and mesoprogestins that inhibit the NF-κB-cyclin D1 axis and blocks the binding of RANKL to RANK can be considered as a potential source of new RANK receptor ligands with anti-RANKL function, which may provide a new perspective into osteoporosis treatment itself as well as limit the osteoporosis rise during breast cancer metastasis to the bone.
format	article
author	Magdalena Woźniczka Katarzyna Błaszczak-Świątkiewicz
author_facet	Magdalena Woźniczka Katarzyna Błaszczak-Świątkiewicz
author_sort	Magdalena Woźniczka
title	New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach
title_short	New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach
title_full	New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach
title_fullStr	New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach
title_full_unstemmed	New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach
title_sort	new generation of meso and antiprogestins (sprms) into the osteoporosis approach
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/7b10aaf7ac6e4049a35883c746c27a12
work_keys_str_mv	AT magdalenawozniczka newgenerationofmesoandantiprogestinssprmsintotheosteoporosisapproach AT katarzynabłaszczakswiatkiewicz newgenerationofmesoandantiprogestinssprmsintotheosteoporosisapproach
_version_	1718431830221258752

New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach

Ejemplares similares